Two separate papers published in the New England Journal of Medicine showed that imetelstat demonstrated disease-modifying activities in phase II studies of myelofibrosis and essential thrombocythemia.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
